Evidence map›Paper›PMID 30021910›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2018

A Novel, Fully Human Anti-fucosyl-GM1 Antibody Demonstrates Potent

Paul Ponath, Daniel Menezes, Chin Pan, Bing Chen, Miho Oyasu, Debbie Strachan, Heidi LeBlanc, Huadong Sun, Xi-Tao Wang, Vangipuram S Rangan and 5 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 2 pooled it
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 2 syntheses or guidelines pooled it, 50 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. A roadmap for translational cancer glycoimmunology at single cell resolution.Journal of experimental & clinical cancer research : CR · 2022
    Review
  14. Review
  15. Review
  16. Role of Fcγ receptors in HER2-targeted breast cancer therapy.Journal for immunotherapy of cancer · 2022
    Review
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 2 countries.

Paul PonathBiologics Discovery California, Bristol-Myers Squibb, Redwood City, California.
Daniel MenezesBiologics Discovery California, Bristol-Myers Squibb, Redwood City, California.
Chin PanBiologics Discovery California, Bristol-Myers Squibb, Redwood City, California.
Bing ChenBiologics Discovery California, Bristol-Myers Squibb, Redwood City, California.
Miho OyasuBiologics Discovery California, Bristol-Myers Squibb, Redwood City, California.
Debbie StrachanBiologics Discovery California, Bristol-Myers Squibb, Redwood City, California.
Heidi LeBlancBiologics Discovery California, Bristol-Myers Squibb, Redwood City, California.
Huadong SunBristol-Myers Squibb, Princeton, New Jersey.
Xi-Tao WangBristol-Myers Squibb, Princeton, New Jersey.
Vangipuram S RanganBiologics Discovery California, Bristol-Myers Squibb, Redwood City, California.
Shrikant DeshpandeBiologics Discovery California, Bristol-Myers Squibb, Redwood City, California.
Sandra CristeaDepartments of Pediatrics and Genetics, Stanford University School of Medicine, Stanford, California.
Kwon-Sik ParkDepartments of Pediatrics and Genetics, Stanford University School of Medicine, Stanford, California.
Julien SageDepartments of Pediatrics and Genetics, Stanford University School of Medicine, Stanford, California.
Pina M CardarelliBiologics Discovery California, Bristol-Myers Squibb, Redwood City, California. pina_cardarelli@comcast.net.
Bristol-Myers Squibb (Germany) · DEStanford University · USBristol-Myers Squibb (United States) · US

Funding

Novel therapeutic approaches for enhancing anti-tumor immunity in SCLCU01CA213273 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI BYERS, LAUREN AVERETT, HEYMACH, JOHN V. · 2017 to 2021
$3.0M
NCI NIH HHS U01 CA213273
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AnimalsAntibody-Dependent Cell CytotoxicityAntigens, NeoplasmAntineoplastic Agents, ImmunologicalCarcinoma, Small CellCell Line, TumorDisease Models, AnimalDose-Response Relationship, DrugDrug Evaluation, PreclinicalG(M1) GangliosideHumansImmunohistochemistryImmunomodulationLung NeoplasmsMiceProtein BindingAntigens, NeoplasmAntineoplastic Agents, ImmunologicalFCGR3A protein, humanfucosyl GM1 gangliosideG(M1) GangliosideReceptors, IgGTumor Necrosis Factor Receptor Superfamily, Member 9

Identifiers

PMID30021910
PMCPMC6499931
OpenAlexW2883600175

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.